# Neuroimaging Data Analytics & Biomarker Data Analysis | IXICO

IXICO's data analytics services deliver secure, compliant neuroimaging and biomarker insights for CNS clinical trials, powered by AI and purpose-built technology.

# Neuroimaging Data Analytics & Biomarker Data Analysis

![Data Analytics](/assets/FullWidthImages/Data-Analytics-v3__ScaleWidthWzEzMTZd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)

Imaging biomarker data interrogated by the IXI™ Platform, together with IXICO’s expert scientists and world-renowned neuroradiologists, translates complex data into clinically meaningful information.

The Platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data that may be generated in the course of a clinical study.

Image analysis algorithms are disease contextualised and data-driven to analyse data from people with specific neurological diseases. Algorithms are also robust to inherent variability between patients, disease stages, scanners and image quality to provide accurate analysis results.

## AI Biomarker Algorithms

Highly differentiated algorithms measuring existing and previously inaccessible biomarkers at scale, with high precision.

- AI-led accurate assessment of brain pathologies and disease-specific symptoms, identifying over 150 brain structures, quantifying the changes in both whole-brain and regional volumes over the time course of a clinical trial.
- Validates measures of function and biochemical characteristics across the identified brain regions.
- Provides trial sponsors with detailed insights into the pipeline drug’s effect on disease progression.
- Regulatory compliant (GCP and 21 CFR Part 11).

## Brain Region Analytics

![Reading Platform](/assets/element-images/Reading-Platform__FitMaxWzk2MCw1NDBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp "Reading Platform")

Performing brain region analysis on individual scans to measure brain volume both at a single time point and across multiple time points.

- Supports critical patient-level decision-making, including providing insights into patient eligibility and drug efficacy.
- ‘Global’ measurements on the whole brain and ‘regional’ measurements of specific local brain regions.
- Human-expert-equivalent analysis at a faster pace and with higher levels of consistency and replicability.
- The capability to be trained on a specific problem using data for a precise brain region in a particular therapeutic indication.
- Regulatory compliant (GCP and CFR 11).

## Highlights

### Consistent

Delivering advanced clinical endpoints while reducing variability by automating traceability and consistent reproducibility into every dataset, all underpinned by a highly granular audit trail.

### Compatible

Reduces data upload, management and analysis burden for sites, sponsors and readers through seamless integration with existing workflows without the need for additional software or tools.

### Flexible

Capabilities in all clinical trial phases, including patient stratification and exploratory endpoints, as well as use for post-market assessment and clinical diagnostics.

### Bespoke

Distinct technologies and scientific expertise to meet specific neurological disease needs with the required specialism and complex understanding of each different indication.